General Information of Drug Combination (ID: DCP6UZN)

Drug Combination Name
BIO-300 Dexrazoxane
Indication
Disease Entry Status REF
Malignant melanoma Investigative [1]
Component Drugs BIO-300   DMJ7NVI Dexrazoxane   DMD7X1O
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: UACC62
Zero Interaction Potency (ZIP) Score: 1.26
Bliss Independence Score: 5.9
Loewe Additivity Score: 6.4
LHighest Single Agent (HSA) Score: 10.67

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Rheumatoid arthritis FA20 Phase 1 [3]
Indication(s) of Dexrazoxane
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [4]
Chemoprotection N.A. Approved [5]
Inflammatory breast cancer 2C62 Approved [6]
Respiratory tract disease CB7Z Investigative [7]
Dexrazoxane Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase II beta (TOP2B) TT4NVEM TOP2B_HUMAN Inhibitor [8]
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Modulator [9]
------------------------------------------------------------------------------------
Dexrazoxane Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Dihydropyrimidinase-related protein 1 (DRP1) DE0EUXB DPYL1_HUMAN Metabolism [10]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DCRZEHO HL-60(TB) Investigative [11]
Adult T acute lymphoblastic leukemia DCAL3TM MOLT-4 Investigative [11]
Anaplastic large cell lymphoma DC037T8 SR Investigative [11]
Chronic myelogenous leukemia DCVQQ2W K-562 Investigative [11]
Clear cell renal cell carcinoma DC7EK3W 786-0 Investigative [11]
Glioblastoma DCTJ6RI SNB-75 Investigative [11]
Colon adenocarcinoma DCZF9AK COLO 205 Investigative [12]
Invasive ductal carcinoma DC7VOX4 BT-549 Investigative [12]
Invasive ductal carcinoma DCPT4T2 HS 578T Investigative [12]
Large cell lung carcinoma DCG1HEZ NCI-H460 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 Clinical pipeline report, company report or official report of Humanetics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7330).
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6 Dexrazoxane FDA Label
7 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
8 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood. Drug Metab Dispos. 2005 Jun;33(6):719-25.
11 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
12 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165